NMN and Exercise Capacity: How NAD+ Affects Endurance and Aerobic Performance

NMN and exercise capacity have become closely linked in recent sports nutrition research as athletes and aging adults alike look for evidence-based ways to sustain aerobic output. Nicotinamide mononucleotide (NMN) is a direct precursor to nicotinamide adenine dinucleotide (NAD+), the coenzyme that drives oxidative phosphorylation in mitochondria. Because endurance performance depends heavily on the rate at which muscle fibers can regenerate ATP aerobically, any intervention that raises NAD+ bioavailability is theoretically positioned to influence how long and how hard a person can train.

What the Research Says About NMN and Exercise Capacity

The human evidence base connecting NMN and exercise capacity is still emerging, but the existing trials share a consistent mechanistic rationale. Most published studies are small-scale, short-duration, and conducted in Japanese or North American cohorts with doses ranging from 250 mg to 1,250 mg per day. The majority measure proxy outcomes—blood NAD+ levels, gait speed, or insulin sensitivity—rather than direct VO₂ max or time-to-exhaustion data. That distinction matters: a compound can raise NAD+ without necessarily translating into measurable endurance gains in every population.

Yoshino et al. (2021) conducted a randomized, placebo-controlled, crossover trial in 25 postmenopausal women with prediabetes. Participants received 250 mg NMN daily for ten weeks. The primary endpoint was muscle insulin sensitivity, measured via hyperinsulinemic-euglycemic clamp. NMN improved insulin-stimulated glucose disposal by approximately 25 percent compared with placebo. While this study did not test maximal aerobic capacity directly, enhanced insulin sensitivity in skeletal muscle is tightly correlated with better substrate utilization during prolonged exercise. The implication for NMN and exercise capacity is that improved metabolic flexibility may allow muscles to oxidize glucose and fatty acids more efficiently during endurance work.

Igarashi et al. (2022) administered 250 mg NMN daily for twelve weeks to 108 older adults with mild sleep disturbance. Blood NAD+ concentrations rose significantly, and subjective fatigue scores improved. Again, no cardiopulmonary exercise test was performed, but reduced perceived fatigue is a recognized contributor to sustained training volume. For readers interested in how NMN timing might influence these outcomes, our companion article on NMN Timing: Fasted or With Food breaks down absorption kinetics and meal interactions.

Fukamizu et al. (2022) gave 1,250 mg NMN daily for four weeks to forty healthy Japanese men aged twenty to sixty-five. The study reported no adverse events and confirmed dose-dependent increases in blood NAM metabolites. Notably, this is one of the highest chronic doses tested in humans to date. The absence of exercise-specific endpoints limits direct inference about NMN and exercise capacity, but the safety profile at this dose supports further athletic-performance trials.

Preclinical data fill some of the mechanistic gaps left by human trials. Mills et al. (2016) administered NMN to aging mice for twelve months and documented improved treadmill endurance, enhanced mitochondrial respiratory capacity, and attenuation of age-related physiological decline. These findings are frequently cited in the exercise context, yet they remain in vivo animal data. Translation to human athletes is not guaranteed. Readers should weigh murine evidence as hypothesis-generating, not proof of performance enhancement in trained humans.

How NAD+ Supports NMN and Exercise Capacity at the Molecular Level

NAD+ exists in two redox states—oxidized (NAD+) and reduced (NADH)—and functions as an essential electron carrier in the citric acid cycle and oxidative phosphorylation. During aerobic exercise, the rate of NAD+ regeneration in mitochondria partly determines how quickly skeletal muscle can resynthesize ATP from ADP. When NAD+ pools decline, as observed with aging and in certain metabolic diseases, mitochondrial efficiency falls and aerobic capacity contracts.

Garten et al. (2015) outlined the central role of nicotinamide phosphoribosyltransferase (NAMPT) in salvaging NAD+ from nicotinamide. NAMPT activity declines with age in multiple tissues, including skeletal muscle, which creates a physiological rationale for supplementing the NAD+ precursor pathway. NMN bypasses the rate-limiting NAMPT step by entering cells directly (or via extracellular conversion to NR) and restoring NAD+ synthesis. In muscle, this replenishment supports sirtuin activity—particularly SIRT1 and SIRT3—which regulate mitochondrial biogenesis, fatty acid oxidation, and antioxidant defenses.

The mechanistic link between NMN and exercise capacity can therefore be summarized as follows: NMN → elevated NAD+ → enhanced mitochondrial electron transport → improved ATP regeneration → greater sustainable aerobic power. This chain is well supported by cell and animal studies; human validation in trained athletes remains the critical missing piece.

Dosage, Form, and Study Design: A Comparison

Not all NMN trials are comparable. The table below summarizes the four primary human studies relevant to NMN and exercise capacity, highlighting dose, duration, population, and measured outcomes.

Study	Dose	Duration	Population	Key Outcome	Relevance to Exercise
Yoshino et al. (2021)	250 mg/day	10 weeks	25 prediabetic women	↑ Muscle insulin sensitivity (~25%)	Indirect: substrate utilization
Igarashi et al. (2022)	250 mg/day	12 weeks	108 older adults	↑ Blood NAD+, ↓ Fatigue	Indirect: training tolerance
Fukamizu et al. (2022)	1,250 mg/day	4 weeks	40 healthy men (20–65 yr)	↑ NAM metabolites, no AE	Safety at high dose; no exercise data
Mills et al. (2016)	~300–500 mg/kg/day*	12 months	Aging C57BL/6 mice	↑ Treadmill endurance	Direct: animal performance data

*Mouse dose scaled from drinking-water concentration; not directly convertible to human equivalents.

Two patterns emerge. First, the doses used in human trials (250–1,250 mg/day) are far below the milligram-per-kilogram exposures used in rodent studies. Second, no human trial to date has employed a standardized exercise-stress protocol such as a graded treadmill test or Wingate anaerobic assessment. That absence means claims about NMN and exercise capacity in humans must be framed as mechanistically plausible but not yet clinically proven.

For individuals weighing NMN against other recovery interventions, hydrogen water has also been studied in exercise contexts. Our review of Hydrogen Water Athletic Recovery covers molecular hydrogen’s effects on delayed-onset muscle soreness and inflammatory markers post-training.

Who Benefits Most from NMN for Exercise Capacity

The strongest theoretical case for NMN and exercise capacity exists in populations where NAD+ decline is most pronounced. Aging adults experience a steady drop in muscle NAMPT expression and total NAD+ content, beginning as early as the third decade of life. For this demographic, NMN supplementation may restore metabolic parameters toward younger physiological baselines, indirectly supporting endurance activities such as cycling, swimming, and distance running. Those interested in age-specific dosing considerations can refer to our article on NMN After 50.

Postmenopausal women with insulin resistance represent another candidate group. Yoshino et al. (2021) demonstrated that NMN improved muscle insulin sensitivity in this cohort, which is relevant because impaired insulin signaling reduces glucose uptake during exercise and limits glycogen replenishment afterward. Better insulin action should, in theory, translate into more consistent energy availability across prolonged training sessions.

Trained endurance athletes are the population most often discussed in popular media, yet they are also the least studied in controlled NMN trials. Young, healthy individuals with already-optimized mitochondrial function may experience smaller incremental gains from NAD+ precursor supplementation. The ceiling effect hypothesis—wherein already-high NAD+ bioavailability leaves little room for further improvement—has not been formally tested, but it is consistent with basic pharmacodynamic principles.

Sleep-disturbed older adults, as studied by Igarashi et al. (2022), may benefit indirectly through reduced fatigue and improved recovery between training bouts. Exercise capacity is not determined solely by what happens during a session; overnight repair and autophagic clearance influence how consistently an individual can accumulate training load across weeks and months.

Practical Takeaways on NMN and Exercise Capacity

• Dose range: Human trials have used 250 mg to 1,250 mg daily. The 250 mg dose has the most direct human efficacy data; higher doses have confirmed safety but limited performance endpoints.
• Duration: Benefits on metabolic parameters appear after 8–12 weeks of consistent supplementation. Acute, single-dose use before an event lacks supporting evidence.
• Population specificity: Older adults and those with early metabolic impairment show the most promising signals. Young, highly trained athletes remain understudied.
• Mechanism alignment: NMN supports mitochondrial NAD+ pools, which in theory enhance aerobic ATP regeneration. This is not the same as stimulant-driven performance enhancement.
• Safety profile: Four-week exposure at 1,250 mg/day and twelve-week exposure at 250 mg/day have been well tolerated in published trials. Long-term athletic-use safety data beyond one year are not available.
• Product quality: If you choose to supplement, select a formulation with verified purity and stability data. PEPAX NMN provides 500 mg per capsule, a dose that aligns with the mid-to-upper range of studied human intakes and allows flexible titration.

For athletes also focused on post-workout muscle repair, the relationship between NAD+ status and skeletal muscle recovery is covered in our article on NMN and Muscle Recovery.

The Bottom Line on NMN and Exercise Capacity

The connection between NMN and exercise capacity is mechanistically coherent and preclinically promising, but human performance data remain sparse. Most studies to date are small-scale, measure metabolic proxies rather than direct endurance endpoints, and have not been replicated in trained athletic populations. NMN is best viewed as a metabolic support compound with a favorable safety profile, not a proven ergogenic aid. Individuals considering NMN for endurance goals should align expectations with the current evidence base and prioritize consistent, longer-term use over acute pre-event dosing.

---

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels in healthy subjects with mild sleep disturbance." NPJ Aging. 2022;8(1):5. [Source]
3. Fukamizu Y, et al. "Effects of orally administered nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Scientific Reports. 2022;12:6134. [Source]
4. Mills KF, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metabolism. 2016;24(6):795–806. [Source]
5. Garten A, et al. "Physiological and pathophysiological roles of NAMPT and NAD metabolism." Nature Reviews Endocrinology. 2015;11(9):535–546. [Source]

---

---